Japanese approvals for Novo’s Ryzodeg, UCB/Otsuka’s Neupro and B-MS … – The Pharma Letter

by admin on December 27, 2012

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS
The Pharma Letter
Neupro is also approved in the EU for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in adults. The drug generated sales of 93 million euros in the first nine months of 2012. Eliquis approved for stroke and AF

and more »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: